Stay updated with breaking news from Step Hfpef. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Positive results from STEP-HFpEF indicate that semaglutide can improve quality of life and functional capacity in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), but large outcomes trials are needed to confirm this, said Javed Butler, MD, MPH, MBA.
Less than 2 weeks after the release of their SELECT reaction podcast, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down for a special edition episode of Diabetes Dialogue to discuss STEP-HFpEF data and the implications for semaglutide 2.4 mg.
Patients who took the therapy lost weight and recorded some of the best gains in quality of life and physical improvement ever seen in this type of a study.